NbN34.0.1 - App Store

Please wait ... The app listing is being verified for availability.
You'll be able to see results in few seconds.


Publisher Description

It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it inform properly the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
This practice is confusing.
. Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided five years ago to establish a taskforce and gave it the mission to embed our current neuroscience advances in the nomenclature.
. The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
. In this second edition 22 new medications were added so NbN includes now 130 medications.
This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.

Therefore this nomenclature is based on:
1. The need to treat now.
2. Updated neuroscience insights.
3. The judgment of the members of the taskforce.
Along these lines, we have come up with the following proposal:
The Nomenclature:
Pharmacology and Mode of Action - reflects the current knowledge and understanding about the targeted neurotransmitter/ molecule/system being modified and the mode/mechanism of action.
We also added 4 additional dimensions
4 Additional Dimensions:
Approved Indications - based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
Efficacy and Side Effects - Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included
Practical Note - Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
Neurobiology - This dimension is focused on the biology. It is divided into preclinical and clinical sections, with the emphasis on the latter
For those who would like to know more abo derived from empirical data.ut the pharmacology, there is a direct link to the relevant site of IUPHAR - our collaborator in this endeavour.

As this is on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertaken.

Version History • The welcome screen now scrolls on small screens, so both options can always be reached
• Layouts stay stable when a larger text size is set on the phone
• Headers stay in place while you scroll
• Updated app icon 4.0.1 10h ago We’ve updated the app with a refreshed design and improved search experience.

• Redesigned onboarding with updated visuals and clearer navigation
• Enhanced search and keyword filtering for more accurate medicine lookups
• Refined medicine detail screens for easier reading and browsing
• Updated app icon and interface improvements across all supported languages 4.0 Sep 21 - Bug fixes. 3.9.5 02/04/2024 - Bug fixes. 3.9.4 12/31/2023 - Bug fixes. 3.9.3 09/27/2023 - Bug fixes. 3.9.2 09/13/2023 - Bug fixes. 3.9.1 07/06/2023 - Bug fixes. 3.9 05/23/2023 - Bug fixes. 3.8 05/09/2023 - Bug fixes. 3.7 05/05/2023 - Bug fixes. 3.6 02/25/2023 It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it properly inform the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
This practice is confusing.
• Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided to establish a taskforce and gave it the mission to embed current neuroscience advances in the nomenclature.
• The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
• In the third edition, 17 new medications were added so that NbN now includes 147 medications. We also introduced the concept of DDDPs – Different Doses Different Pharmacology (see for example - Doxepin). Additionally, we updated relevant data, especially regarding neurobiology.
This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.

Therefore this nomenclature is based on:
1. The need to treat now.
2. Updated neuroscience insights.
3. The judgment of the members of the taskforce.
Along these lines, we have come up with the following proposal:
The Nomenclature:
Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/molecule/system being modified and the mode/mechanism of action.
We also added 5 dimensions:
Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included
Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
Pregnancy – Potential risk of taking the particular medication during pregnancy
Neurobiology – This dimension focuses on biology. It is divided into preclinical and clinical sections, with an emphasis on the latter.

As this is an on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertake 3.5 02/24/2023 It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it properly inform the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
This practice is confusing.
• Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided to establish a taskforce and gave it the mission to embed current neuroscience advances in the nomenclature.
• The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
• In the third edition, 17 new medications were added so that NbN now includes 147 medications. We also introduced the concept of DDDPs – Different Doses Different Pharmacology (see for example - Doxepin). Additionally, we updated relevant data, especially regarding neurobiology.
This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.

Therefore this nomenclature is based on:
1. The need to treat now.
2. Updated neuroscience insights.
3. The judgment of the members of the taskforce.
Along these lines, we have come up with the following proposal:
The Nomenclature:
Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/molecule/system being modified and the mode/mechanism of action.
We also added 5 dimensions:
Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included
Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
Pregnancy – Potential risk of taking the particular medication during pregnancy
Neurobiology – This dimension focuses on biology. It is divided into preclinical and clinical sections, with an emphasis on the latter.
As this is an on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertake 3.4 01/11/2022 It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it properly inform the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
This practice is confusing.
• Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided to establish a taskforce and gave it the mission to embed current neuroscience advances in the nomenclature.
• The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
• In the third edition, 17 new medications were added so that NbN now includes 147 medications. We also introduced the concept of DDDPs – Different Doses Different Pharmacology (see for example - Doxepin). Additionally, we updated relevant data, especially regarding neurobiology.
This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.

Therefore this nomenclature is based on:
1. The need to treat now.
2. Updated neuroscience insights.
3. The judgment of the members of the taskforce.
Along these lines, we have come up with the following proposal:
The Nomenclature:
Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/molecule/system being modified and the mode/mechanism of action.
We also added 5 dimensions:
Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included
Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
Pregnancy – Potential risk of taking the particular medication during pregnancy
Neurobiology – This dimension focuses on biology. It is divided into preclinical and clinical sections, with an emphasis on the latter.
As this is an on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertake 3.3 11/24/2021 Performance improvements 3.1 08/12/2021 Performance improvements 3.0 08/11/2021 In this version of the app, we fixed some technical issues and added important information and tools such as: a tutorial video of the app., the mission and scope of the NbN, and lists of the 10 pharmacological domains and 9 modes of action used to classify psychotropics.‏‎ 2.9 11/26/2020 In this new version, we have included new information on doses for each drug. Another change is related to nomenclature; it was simplified, (e.g., instead of talking about “serotonin reuptake inhibitor” we now use “serotonin inhibitor”), yet the extended terminology is brought as the first line in the neurobiology layer. Furthermore we improved and updated the search engine logic for a better and more intuitive user experience. 2.7 08/04/2019 General improvements 2.6 08/29/2018 General improvements 2.5 08/26/2018 General improvements. 2.4 05/08/2018 General improvements 2.3 01/09/2018 IOS 11 bug fixes. 2.2 11/05/2017 General improvements 2.1 08/29/2017 In this updated version we improve and optimize NbN search engine logic by dimensions in order to shorten user search time. Furthermore additional drug were added according to ECNP committee recommendation.
The new and updated version of NbN-2 is an English version, translation to choosen languages will follow. 2.0 05/08/2017



About NbN3

NbN3 is a free app for iOS published in the Health & Nutrition list of apps, part of Home & Hobby.

The company that develops NbN3 is ECNP Research and Scholarship Stichting (De ECNP Research and Scholarship Foundation). The latest version released by its developer is 4.0.1.

To install NbN3 on your iOS device, just click the green Continue To App button above to start the installation process. The app is listed on our website since 2026-10-15 and was downloaded 0 times. We have already checked if the download link is safe, however for your own protection we recommend that you scan the downloaded app with your antivirus. Your antivirus may detect the NbN3 as malware if the download link is broken.

How to install NbN3 on your iOS device:

  • Click on the Continue To App button on our website. This will redirect you to the App Store.
  • Once the NbN3 is shown in the iTunes listing of your iOS device, you can start its download and installation. Tap on the GET button to the right of the app to start downloading it.
  • If you are not logged-in the iOS appstore app, you'll be prompted for your your Apple ID and/or password.
  • After NbN3 is downloaded, you'll see an INSTALL button to the right. Tap on it to start the actual installation of the iOS app.
  • Once installation is finished you can tap on the OPEN button to start it. Its icon will also be added to your device home screen.

Program Details



Category

Category
Subcategory

System requirements

Operating systems
iOS

Download information

File size
25 bytes
Total downloads
0

Pricing

License model
Free
Price

Version History


Here you can find the changelog of NbN3 since it was posted on our website on 2026-11-04.The latest version is 4.0.1 and it was updated on Apps112 on 04 November, 2026.See below the changes in each version:

version 4.0.1

posted on 2026-10-15

Version History • The welcome screen now scrolls on small screens, so both options can always be reached
• Layouts stay stable when a larger text size is set on the phone
• Headers stay in place while you scroll
• Updated app icon 4.0.1 10h ago We’ve updated the app with a refreshed design and improved search experience.

• Redesigned onboarding with updated visuals and clearer navigation
• Enhanced search and keyword filtering for more accurate medicine lookups
• Refined medicine detail screens for easier reading and browsing
• Updated app icon and interface improvements across all supported languages 4.0 Sep 21 - Bug fixes. 3.9.5 02/04/2024 - Bug fixes. 3.9.4 12/31/2023 - Bug fixes. 3.9.3 09/27/2023 - Bug fixes. 3.9.2 09/13/2023 - Bug fixes. 3.9.1 07/06/2023 - Bug fixes. 3.9 05/23/2023 - Bug fixes. 3.8 05/09/2023 - Bug fixes. 3.7 05/05/2023 - Bug fixes. 3.6 02/25/2023 It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it properly inform the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
This practice is confusing.
• Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided to establish a taskforce and gave it the mission to embed current neuroscience advances in the nomenclature.
• The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
• In the third edition, 17 new medications were added so that NbN now includes 147 medications. We also introduced the concept of DDDPs – Different Doses Different Pharmacology (see for example - Doxepin). Additionally, we updated relevant data, especially regarding neurobiology.
This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.

Therefore this nomenclature is based on:
1. The need to treat now.
2. Updated neuroscience insights.
3. The judgment of the members of the taskforce.
Along these lines, we have come up with the following proposal:
The Nomenclature:
Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/molecule/system being modified and the mode/mechanism of action.
We also added 5 dimensions:
Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included
Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
Pregnancy – Potential risk of taking the particular medication during pregnancy
Neurobiology – This dimension focuses on biology. It is divided into preclinical and clinical sections, with an emphasis on the latter.

As this is an on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertake 3.5 02/24/2023 It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it properly inform the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
This practice is confusing.
• Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided to establish a taskforce and gave it the mission to embed current neuroscience advances in the nomenclature.
• The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
• In the third edition, 17 new medications were added so that NbN now includes 147 medications. We also introduced the concept of DDDPs – Different Doses Different Pharmacology (see for example - Doxepin). Additionally, we updated relevant data, especially regarding neurobiology.
This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.

Therefore this nomenclature is based on:
1. The need to treat now.
2. Updated neuroscience insights.
3. The judgment of the members of the taskforce.
Along these lines, we have come up with the following proposal:
The Nomenclature:
Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/molecule/system being modified and the mode/mechanism of action.
We also added 5 dimensions:
Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included
Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
Pregnancy – Potential risk of taking the particular medication during pregnancy
Neurobiology – This dimension focuses on biology. It is divided into preclinical and clinical sections, with an emphasis on the latter.
As this is an on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertake 3.4 01/11/2022 It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it properly inform the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
This practice is confusing.
• Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided to establish a taskforce and gave it the mission to embed current neuroscience advances in the nomenclature.
• The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
• In the third edition, 17 new medications were added so that NbN now includes 147 medications. We also introduced the concept of DDDPs – Different Doses Different Pharmacology (see for example - Doxepin). Additionally, we updated relevant data, especially regarding neurobiology.
This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.

Therefore this nomenclature is based on:
1. The need to treat now.
2. Updated neuroscience insights.
3. The judgment of the members of the taskforce.
Along these lines, we have come up with the following proposal:
The Nomenclature:
Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/molecule/system being modified and the mode/mechanism of action.
We also added 5 dimensions:
Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included
Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
Pregnancy – Potential risk of taking the particular medication during pregnancy
Neurobiology – This dimension focuses on biology. It is divided into preclinical and clinical sections, with an emphasis on the latter.
As this is an on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertake 3.3 11/24/2021 Performance improvements 3.1 08/12/2021 Performance improvements 3.0 08/11/2021 In this version of the app, we fixed some technical issues and added important information and tools such as: a tutorial video of the app., the mission and scope of the NbN, and lists of the 10 pharmacological domains and 9 modes of action used to classify psychotropics.‏‎ 2.9 11/26/2020 In this new version, we have included new information on doses for each drug. Another change is related to nomenclature; it was simplified, (e.g., instead of talking about “serotonin reuptake inhibitor” we now use “serotonin inhibitor”), yet the extended terminology is brought as the first line in the neurobiology layer. Furthermore we improved and updated the search engine logic for a better and more intuitive user experience. 2.7 08/04/2019 General improvements 2.6 08/29/2018 General improvements 2.5 08/26/2018 General improvements. 2.4 05/08/2018 General improvements 2.3 01/09/2018 IOS 11 bug fixes. 2.2 11/05/2017 General improvements 2.1 08/29/2017 In this updated version we improve and optimize NbN search engine logic by dimensions in order to shorten user search time. Furthermore additional drug were added according to ECNP committee recommendation.
The new and updated version of NbN-2 is an English version, translation to choosen languages will follow. 2.0 05/08/2017

Disclaimer


Official App Store Link


We do not host NbN3 on our servers. We did not scan it for viruses, adware, spyware or other type of malware. This app is hosted by Apple and passed their terms and conditions to be listed there. We recommend caution when installing it.

The App Store link for NbN3 is provided to you by apps112.com without any warranties, representations or guarantees of any kind, so access it at your own risk.

If you have questions regarding this particular app contact the publisher directly. For questions about the functionalities of apps112.com contact us.





Click stars to rate this APP!

Users Rating:
  0.0/5     0
Downloads: 0
Updated At: 2026-11-04
Operating System: iOS
License Type: Free

TOP DOWNLOADS
in Home & Hobby last week